Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02687984
Recruitment Status : Completed
First Posted : February 23, 2016
Last Update Posted : January 31, 2017
Sponsor:
Information provided by (Responsible Party):
Indivior Inc.

Brief Summary:

Primary Objective: To assess the relative bioavailability of RBP-7000 formulated with 2 different molecular weights (MW) (low and high MW as test treatments) of poly (DL-lactide-co-glycolide) with a carboxylic acid end group (PLGH) polymer compared to intermediate MW PLGH polymer following single subcutaneous (SC) injection of RBP-7000 in subjects with stable schizophrenia.

Secondary Objective:

To evaluate the safety and tolerability of single SC injections of RBP-7000 using a PLGH polymer of 2 different MW (low and high MW as test treatments) compared to intermediate MW polymer in subjects with stable schizophrenia.


Condition or disease Intervention/treatment Phase
Schizophrenia Drug: RBP-7000 Phase 1

Detailed Description:
This is a multicenter, randomized, open-label, single-dose, parallel-group study in subjects with clinically stable schizophrenia who are not currently taking risperidone. A total of approximately 48 subjects (16 per group) will be randomized to receive a single subcutaneous (SC) injection of RBP-7000 120 mg formulated with PLGH polymer of either 21 kilodaltons (kDa) (low MW group), 29 kDa of PLGH polymer (high MW group), or 26 kDa of PLGH polymer (intermediate MW group).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of RBP-7000 Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) Compared to Intermediate Molecular Weight (Reference Treatment) Polymer in Subjects With Schizophrenia
Study Start Date : February 2016
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Risperidone

Arm Intervention/treatment
Experimental: RBP-7000 PLGH A
A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
Drug: RBP-7000
A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Other Name: Risperdal

Experimental: RBP-7000 PLGH B
A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
Drug: RBP-7000
A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Other Name: Risperdal

Active Comparator: RBP-7000 PLGH C
A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
Drug: RBP-7000
A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
Other Name: Risperdal




Primary Outcome Measures :
  1. Initial Burst Parameters: Cmax of risperidone [ Time Frame: approximately 0-24 hours; Day 1 to Day 2 ]
    Maximum observed plasma concentration

  2. Initial Burst Parameters: AUC0-24h of risperidone [ Time Frame: approximately 0-24 hours; Day 1 to Day 2 ]
    Area under the plasma concentration-time curve from time 0 to 24 hours post-dose; calculated using the linear trapezoidal rule.

  3. Secondary Peak Parameters: Cmax of risperidone [ Time Frame: approximately 24-672 hours; Day 2 to Day 29 ]
    Maximum observed plasma concentration

  4. Secondary Peak Parameters: AUCD2-D29 of risperidone [ Time Frame: approximately 24-672 hours; Day 2 to Day 29 ]
    Area under the plasma concentration-time curve from 24 hours post-dose (Day 2) to 672 hours post-dose (Day 29); calculated using the linear trapezoidal rule.

  5. Overall Parameters: Cmax of risperidone [ Time Frame: Day 1 to Day 29 ]
    Maximum observed plasma concentration

  6. Overall Parameters: AUCD1-D29 of risperidone [ Time Frame: Day 1 to Day 29 ]
    Area under the plasma concentration-time curve from time 0 (Day 1) to 672 hours post-dose (Day 29); calculated using the linear trapezoidal rule.


Secondary Outcome Measures :
  1. Initial Burst Parameters: Cmax of 9-hydroxyrisperidone [ Time Frame: approximately 0-24 hours; Day 1 to Day 2 ]
    Maximum observed plasma concentration

  2. Initial Burst Parameters: AUC0-24h of 9-hydroxyrisperidone [ Time Frame: approximately 0-24 hours; Day 1 to Day 2 ]
    Area under the plasma concentration-time curve from time 0 to 24 hours post-dose; calculated using the linear trapezoidal rule.

  3. Secondary Peak Parameters: Cmax of 9-hydroxyrisperidone [ Time Frame: approximately 24-672 hours; Day 2 to Day 29 ]
    Maximum observed plasma concentration

  4. Secondary Peak Parameters: AUCD2-D29 of 9-hydroxyrisperidone [ Time Frame: approximately 24-672 hours; Day 2 to Day 29 ]
    Area under the plasma concentration-time curve from 24 hours post-dose (Day 2) to 672 hours post-dose (Day 29); calculated using the linear trapezoidal rule.

  5. Overall Parameters: Cmax of 9-hydroxyrisperidone [ Time Frame: Day 1 to Day 29 ]
    Maximum observed plasma concentration

  6. Overall Parameters: AUCD1-D29 of 9-hydroxyrisperidone [ Time Frame: Day 1 to Day 29 ]
    Area under the plasma concentration-time curve from time 0 (Day 1) to 672 hours post-dose (Day 29); calculated using the linear trapezoidal rule.

  7. Summary of Participants with Adverse Events [ Time Frame: Day 1 to Day 29 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia as defined by DSM-5 criteria.
  • Clinically stable schizophrenia, as evidenced by the investigator evaluation, outpatient status for at least 30 days prior to screening, and confirmation of stability by a caregiver who has regular supportive contact with the subject.
  • Otherwise healthy on the basis of physical examination.
  • Body mass index (BMI) between 18 and 35 kg/m^2 and weight of at least 49.9 kg at screening.

Exclusion Criteria:

  • Subjects taking any oral risperidone product (except the test doses of 0.25 mg of risperidone); or subjects taking any risperidone or 9-hydroxyrisperidone sustained-release or depot formulation within 120 days prior to study screening; or subjects who have received the 3-month depot formulation of 9-hydroxyrisperidone within 2 years of study screening.
  • Subjects taking a clinically relevant inducer or inhibitor of cytochrome P450 (CYP) 2D6, or CYP3A4, who have not undergone proper washout (minimum of 5 half-lives of the medication) of this prohibited medication prior to Day 1.
  • Medications, which in the opinion of the Investigator in conjunction with the medical monitor, may be expected to significantly interfere with metabolism or excretion of risperidone and/or 9-hydroxyrisperidone; may be associated with a significant drug interaction with risperidone; or may pose a significant risk to a subject's participation in the study.
  • Any natural products or herbal preparations including all vitamins and supplements throughout the study.
  • Subjects with a history of cancer unless disease-free for ≥5 years (with the exception of resected basal cell or squamous cell carcinoma of the skin).
  • Subjects with any other active medical condition/disorder/disease that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug.
  • Subjects that had an exacerbation of schizophrenia in the last 30 days.
  • Subjects with evidence or history (in the past 6 months prior to screening) of a significant hepatic disorder that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug, including:
  • Acute or chronic hepatitis, including but not limited to hepatitis B or C.
  • Total bilirubin >1.5 x the upper limit of normal (ULN), or
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2x ULN.
  • Subjects with a history of severe renal disease, or creatinine clearance <60 mL/min
  • Subjects with evidence or history of orthostatic hypotension within 6 months of screening.
  • Subjects with absolute neutrophil count <1.5x 10^9/L (African and African/American <1.2x 10^9/L).
  • Subjects with a history of drug-induced leucopenia.
  • Subjects who have acquired immune deficiency syndrome (AIDS) or to be human immunodeficiency virus (HIV)-positive.
  • Subjects with other medical conditions including, but not limited to, history of heart attack (myocardial infarction) or brain injury (traumatic injury with loss of consciousness and/or cerebrovascular accident), or clinically significant low blood pressure or arrhythmias as interpreted by the Principal Investigator or medically qualified sub-investigator.
  • Subjects with congenital long QT syndrome, history of prolonged QT in the 3 months prior to screening, or a corrected QT interval (Fridericia - QTcF) >450 msec (male) or >470 msec (female) at screening (Visit 1).
  • Subjects with suicidal ideation with intent or plan
  • Subjects with uncontrolled depression, in the opinion of the Investigator.
  • Subjects with a diagnosis of insulin-dependent diabetes, or who have a hemoglobin A1c (HbA1c) ≥8.0% at screening, or have had changes in diabetic medication regimen in the 28 days prior to signing the informed consent document.
  • Subjects with prior allergic reactions, sensitivities or other known contraindications to any component of RBP-7000 (e.g., risperidone, PLGH or NMP).
  • Women of childbearing potential who are pregnant or breastfeeding, seeking pregnancy, or failing to use adequate contraceptive methods during the study.
  • Subjects with the presence of opioids, cocaine, amphetamines, methadone, barbiturates, benzodiazepines, methamphetamines, cannabinoids, or phencyclidine in the urine as assessed by a urine drug screen.
  • Subjects with epilepsy or other seizure disorders, Parkinson's disease or dementia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02687984


Locations
Layout table for location information
United States, California
Collaborative Neuroscience Network, LLC
Garden Grove, California, United States, 92845
Collaborative Neuroscience Network
Torrance, California, United States, 90502
Sponsors and Collaborators
Indivior Inc.
Investigators
Layout table for investigator information
Study Director: Study Director Indivior Inc.

Layout table for additonal information
Responsible Party: Indivior Inc.
ClinicalTrials.gov Identifier: NCT02687984     History of Changes
Other Study ID Numbers: RB-US-15-0001
First Posted: February 23, 2016    Key Record Dates
Last Update Posted: January 31, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Indivior Inc.:
Schizophrenia
Long-acting Risperidone
Atrigel
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Risperidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents